



# Epidemiology of a Pertussis Outbreak in Central Saskatchewan First Nations Communities

Presented by:

**Michelle Allard-Johnson BScN, RN**  
Regional Immunization Coordinator  
First Nations Inuit Health Branch-SK



Indigenous Services  
Canada

Services aux  
Autochtones Canada

Canada

# Disclosure Statement

- I have no affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization.

# Co-authors

- Mustafa Andkhoie
- Carolyn Cyr
- Leslie Ann Smith
- Colleen Bowen
- Denise Kopp
- Dr. Rosemarie Ramsingh
- Dr. Ibrahim Khan
- Germain Bukassa-Kassadi
- Jolene Blocka
- Paige Henri
- Bodiene Dussion
- Amanda St-Onge
- Eno Lindsay
- Dawn Garner
- Irene Fineday
- Sandra Untereiner
- Nolan Claude
- Deborah Kupchanko

# Definitions

An individual's vaccine coverage measure is defined as

- “on-time”: receipt of the full number of pertussis vaccine doses by a certain age when they are suppose to be, as per the Saskatchewan provincial guidelines.
- “up-to-date”: receipt of the full number of valid and required pertussis vaccine doses by a certain age, given they are not “on-time”.
- “behind”: not received at least one or more of the required pertussis vaccines by a certain age.

# Purpose

The purpose of this analysis is to:

1. Determine whether the pertussis vaccine coverage measure of an individual by the age of 18 months is associated with the odds of being diagnosed as a pertussis case in this outbreak.
2. Determine whether the number of years passed since the last pertussis vaccine (among 4 years olds to 13 years olds) is associated with the odds of being diagnosed as a pertussis case in this outbreak.

# Methods

- Data compiled by the communities and FNIHB using paper chart reviews.
- Analysis included descriptive statistics and multivariable binary logistics regression models:
  - Variables of interest are pertussis vaccine coverage measure, time since last pertussis vaccine received, age, gender and community of residence.
  - Only variables unconditionally associated with the outcomes ( $p<0.2$ ) were included in the manual model building process.
  - Manual backwards elimination procedure was used to build the final multivariable models.
  - Only significant variables ( $p<0.05$ ) and confounders were retained (adjusted odds ratio changing  $>20\%$ ).
  - All possible two-way interactions among main-effects variables were tested.
  - Model diagnostics conducted the using receiver operating curve and plots of standardized residuals.
    - no evidence of any issues with model fitness
  - Analysis conducted using Microsoft Excel 2010 and Stata™ IC 14.1.


## Results – Descriptive statistics

Variable	Case	Contact
<b>Gender</b>		
Female	15	121
Male	7	109
Unknown	0	9
<b>Age Groups</b>		
2 to 9 years old	12	82
10 to 17 years old	7	64
18+	3	83
Unknown	0	10
<b>Total</b>	<b>22</b>	<b>239</b>

## Results – Model 1

*Odds of being diagnosed as a pertussis case based on the pertussis vaccine coverage measure at 18 months of age*

**Individuals had nearly five times higher odds of being diagnosed with pertussis in this outbreak if they were “behind” in their pertussis vaccine coverage measure at 18 months of age** compared to the individuals who were either “on-time” or “up-to-date”.




\*other variables were not significant or confounding.

## Results – Model 2

*Odds of being diagnosed as a pertussis case among those children 4 to 13 years old in this outbreak*

**Children (age 4 to 13 yo) had several times higher odds of being diagnosed with pertussis in this outbreak if they received their last pertussis dose more than 3 years ago compared to the same age group of children who were vaccinated within the past 3 years.**

Less than 3  
years since  
last pertussis  
vaccine



\*after controlling for confounders

- gender
- pertussis vaccine coverage measure at 4-6 years of age

The above two variables were not statistically significant but were included in the final model because they were identified as confounders.

# **Key Take-Aways and Important Implementations regarding a pertussis outbreak response:**

- Vulnerable people are the priority for clinical and public health response (children under 1 year and pregnant women last trimester)
- Immunization is the most effective means of control
- Enhanced immunization in last trimester pregnant women
- Communication is key!
  - Health Directors/Chief and Council
  - Nurses in the “field”
  - Team members (CD and Immunization coordinators, administrative staff, others)
  - Family Physicians/Primary Care
- Awareness of “Outbreak fatigue” in staff on the ground during ongoing outbreaks

## In Saskatchewan:

- Current Pertussis vaccine schedule:
  - 2, 4 and 6 months
  - 18 months
  - 4-6 years
  - Grade 8
  - 1 dose in adulthood (18 years of age and older)
  - As of October 1, 2017, all pregnant women are to be offered a dose of Pertussis containing vaccine (Tdap) in the third trimester of every pregnancy (on or after 27 weeks gestation).

# Points to Ponder

## Timeliness and Effectiveness of the Pertussis Vaccine

- Waning immunity of pertussis vaccine
  - Increase in Pertussis disease among vaccinated populations
  - Additional doses of Pertussis containing vaccines in early school years
- The effect of delayed pertussis vaccination
  - Under vaccinated children are more at risk
  - Timeliness of vaccination also contributes to risk
- Additional doses of Tetanus and Diphteria antigens
  - unnecessary

# Take forward

- Increasing Pertussis Vaccine effectiveness
  - Countries using aP vaccines (additional boosters)

# References

- National Collaborating Centre for Infectious Diseases. Disease debrief: Pertussis [Internet]. Winnipeg (MB): National Collaborating Centre for Infectious Diseases; 2017 [cited Nov 26]. Available from: <https://nccid.ca/debrief/pertussis/>
- Locht C. Will we have new pertussis vaccine? *Vaccine* 2018;36(36):5460-5469. <https://doi.org/10.1016/j.vaccine.2017.11.055>
- Halperin SA. Pertussis: A global perspective. Public Health Agency of Canada: CCDR 2014;40-3:55-58. <https://doi.org/10.14745/ccdr.v40i03a05>
- Glanz J, Narwaney K, Newcomer S, Daley M, Hambridge S, Rowhani-Rahbar A, et al. Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age. *JAMA Pediatr* 2013;167(11):1060-1064. doi:10.1001/jamapediatrics.2013.2353
- Curran D, Terlinden A, Poirrier JE, Masseria C, Krishnarajah G. A cost analysis of the potential implications of delayed pertussis vaccination in the US. *Pediatr Infect Dis J* 2016;35:542–547.

## References con't

- Xianfang CL, Christopher AB, Kimberley AS, Lawrence WS, Sumana F, Steven JD, et al. Epidemiology of pertussis in Alberta Canada 2004-2015. *BMC Public Health* 2017;17:539
- Olin P, Gustafsson L, Barreto L, Hessel L, Mast C, Rie AV, Bogaerts H, Storsaeter J. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. *Vaccine* 2003;21:2015-2021. [https://doi.org/10.1016/S0264-410X\(02\)00777-6](https://doi.org/10.1016/S0264-410X(02)00777-6)
- Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, et al. Waning immunity to pertussis following 5 doses of DTaP. *Pediatrics* 2013;131:e1047-e1052
- Carollo M, Pandolfi E, Tozzi AE, Buisman AM, Mascart F, Ausiello CM. Humoral and B-cell memory responses in children five years after pertussis acellular vaccine priming. *Vaccine* 2014;32(18):2093-9. DOI:[10.1016/j.vaccine.2014.02.005](https://doi.org/10.1016/j.vaccine.2014.02.005)

## References con't

- McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: A meta-analysis. *Pediatrics* 2015;135(2):331-43. DOI:[10.1542/peds.2014-1729](https://doi.org/10.1542/peds.2014-1729)
- Acosta AM, DeBolt C, Tasslimi A, Lewis M, Stewart LK, Misegades LK, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. *Pediatrics* 2015;135(6):981-9. DOI:[10.1542/peds.2014-3358](https://doi.org/10.1542/peds.2014-3358)
- Schwartz K, Kwong J, Deeks S, Campitelli M, Jamieson F, Marchand-Austin A, et al. Effectiveness of pertussis vaccination and duration of immunity. *CMAJ* 2016;188(16):E399-E406. DOI:10.1503/cmaj.160193
- World Health Organization. Pertussis vaccines: WHO position paper-August 2015; 35(90):433-460. Available from:  
<http://www.who.int/wer/2015/wer9035.pdf?ua=1>

- Question?

- Thanks!